Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy
October 22, 2020 07:00 ET
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...
Adicet Bio to Present at the Jefferies Cell Therapy Summit
October 01, 2020 16:10 ET
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...
Adicet Bio Appoints Nick Harvey as Chief Financial Officer
September 16, 2020 07:00 ET
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...
Adicet Bio to Present at the Cantor Virtual Global Healthcare Conference
September 15, 2020 16:10 ET
|
Adicet Bio, Inc.
MENLO PARK, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and...
Adicet Announces Completion of Merger with resTORbio
September 15, 2020 08:55 ET
|
resTORbio, Inc.
- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol “ACET”- ...